Bifidobacterium breve and application thereof

Abstract

The application discloses a Bifidobacterium breve and application thereof, and belongs to the technical field of microorganisms. The Bifidobacterium breve CCFM1310 provided by the application has the functions of improving immune organs, increasing the number of white blood cells in blood, up-regulating the activities of acid phosphatase (ACP) and lactate dehydrogenase (LDH), increasing the contents of immunoglobulin IgA, IgG and IgM in serum, regulating intestinal flora and the like, and can improve the immune capacity of the body by increasing the organ index, non-specific immune response and specific immune response of the body. The strain provided by the application can be used as a daily intake of probiotics to replace drugs for improving the immune capacity of the human body, and can be used as a new choice for treating patients with low immunity.

Description

Technical Field

[0001] This invention relates to a strain of Bifidobacterium breve and its applications, belonging to the field of microbial technology. Background Technology

[0002] Probiotics refer to a class of live microorganisms that produce beneficial effects on the host. By colonizing the host's gut and reproductive system, they can produce definite health benefits, thereby improving the host's microecological balance. Lactic acid bacteria, as the most representative genus of probiotics, possess physiological activities such as aiding digestion, promoting nutrient absorption, alleviating lactose intolerance, preventing and treating diarrhea, regulating gut microbiota and relieving constipation, regulating immune function, lowering total blood cholesterol, improving food-induced allergies, delaying aging, and anti-tumor activity.

[0003] Early research primarily focused on the discovery of probiotics and their regulatory effects on the gut microbiota. In recent years, increasing research has shown that probiotics can enhance immune function by regulating the structure and function of the gut microbiota. In animal models and clinical trials, probiotics have demonstrated their role in regulating immune activity through multiple pathways, including increasing the number and function of immune cells, promoting the production and release of immunoglobulins, strengthening the mucosal immune barrier, and reducing inflammatory responses. Many types of Bifidobacteria are available on the market to improve immunity, with some common strains including *Bifidobacterium animalis* BB12 from Chr. Hansen (Denmark) and *Lactobacillus rhamnosus* LGG from Vilio (Finland). However, very few domestically developed immunomodulatory strains possess independent intellectual property rights, and even fewer have successfully entered the market. Currently, *Bifidobacterium* and *Lactobacillus casei* are among the most studied strains both domestically and internationally. However, due to the strain-specific nature of probiotic viability, there are significant differences in viability between different strains. Therefore, there is an urgent need to screen probiotics that regulate the body's immune activity. Summary of the Invention

[0004] This invention provides a short Bifidobacterium strain with immune-enhancing capabilities ( Bifidobacterium breve CCFM1310 was deposited on June 7, 2023, at the Guangdong Provincial Center for Microbial Culture Collection, with accession number GDMCC No: 63536, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0005] The present invention provides a drug containing the aforementioned Bifidobacterium breve CCFM1310.

[0006] The present invention also provides the application of the aforementioned Bifidobacterium breve CCFM1310 in the preparation of drugs that enhance the body's immunity.

[0007] In one embodiment, the application includes modulating the body's non-specific immune function, specific immune function, and intestinal immune function.

[0008] In one implementation, the application includes, but is not limited to, at least one of the following functions:

[0009] (1) Restore the abnormally low levels of white blood cells and neutrophils;

[0010] (2) Improve spleen tissue damage;

[0011] (3) Increase the content of humoral immunoglobulins;

[0012] (4) Restore the abnormally low activity of spleen LDH enzyme and ACP enzyme.

[0013] In one embodiment, the application also includes regulating the gut microbiota.

[0014] In one embodiment, the viable count of *Bifidobacterium breve* CCFM1310 in the drug is not less than 1 × 10⁻⁶. 10 CFU / g.

[0015] In one embodiment, the drug contains the Bifidobacterium breve CCFM1310, a drug carrier, and / or pharmaceutical excipients.

[0016] The present invention also provides a composition containing the aforementioned Bifidobacterium breve CCFM1310.

[0017] In one embodiment, the composition includes, but is not limited to, food, health products, or microbial preparations.

[0018] In one embodiment, the composition is a starter culture containing Bifidobacterium breve CCFM1310.

[0019] In one embodiment, the fermenting agent is obtained by culturing the Bifidobacterium breve CCFM1310 in a culture medium for a period of time, collecting the bacterial cells in the cell culture medium, and using them directly as the fermenting agent or by treating the bacterial cells to obtain the fermenting agent.

[0020] In one embodiment, the process includes, but is not limited to, one or more of the following methods: washing, adding a protective agent, drying, etc.

[0021] In one embodiment, the fermentation agent is prepared as follows: Bifidobacterium breve CCFM1310 is inoculated into the culture medium at an inoculation rate of 1% to 5% of the total mass of the culture medium, and cultured at 37°C for 18 h. The culture medium is then centrifuged to obtain bacterial cells. The bacterial cells are then resuspended in physiological saline to obtain the fermentation agent.

[0022] In one embodiment, the culture medium is mMRS medium; the mMRS medium is an MRS medium supplemented with cysteine ​​hydrochloride.

[0023] In one embodiment, the food includes dairy products, soy products, meat products, or fruit and vegetable products produced using the fermentation agent of the aforementioned Bifidobacterium breve CCFM1310.

[0024] The present invention also provides the use of the aforementioned Bifidobacterium breve CCFM1310 in the preparation of health products that help enhance immunity.

[0025] The present invention also provides the application of Bifidobacterium breve CCFM1310 in food additives, including but not limited to its use as a food fermentation agent.

[0026] Beneficial Effects: This invention provides a strain of Bifidobacterium breve CCFM1310 with immunomodulatory functions. This strain can regulate immunity as a single strain, and by modulating the body's non-specific and specific immune functions, it can enhance the body's immunity. Furthermore, Bifidobacterium breve CCFM1310 can effectively increase the levels of immunoglobulins IgA, IgG, and IgM, improve thymic atrophy and splenomegaly induced by cyclophosphamide, increase the number of white blood cells in peripheral blood, and regulate the activity of immune-related enzymes and intestinal flora. The strain of this invention can be taken as a probiotic in daily intake, replacing existing drugs to improve human immunity, and can serve as a new option for treating patients with low immunity. The strain of this invention can also be used as a pharmaceutical compound.

[0027] Preservation of biological materials

[0028] Bifidobacterium breve ( Bifidobacterium breve (CCFM1310, categorized as follows) Bifidobacterium breve It was deposited on June 7, 2023, at the Guangdong Provincial Center for Microbial Culture Collection, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with accession number GDMCC No: 63536. Attached Figure Description

[0029] Figure 1 The image shows the effect of gavage administration of the present invention, Bifidobacterium breve CCFM1310, on immune organ indices in BALB / c mice.

[0030] Figure 2 The figure shows the distribution of white blood cell count in peripheral blood, indicating that Bifidobacterium breve CCFM1310 can increase the number of white blood cells.

[0031] Figure 3The H&E staining of spleen tissue in each group is shown, indicating that Bifidobacterium breve CCFM1310 can alleviate spleen damage caused by modeling.

[0032] Figure 4 The H&E staining of small intestinal tissues in each group is shown, indicating that Bifidobacterium breve CCFM1310 can alleviate small intestinal damage caused by modeling.

[0033] Figure 5 The figure shows the level of immunoglobulins in serum, indicating that Bifidobacterium breve CCFM1310 can increase the levels of immunoglobulins IgA, IgG and IgM in the body.

[0034] Figure 6 The figure shows the activity of lactate dehydrogenase (LDH) in the spleen, indicating that Bifidobacterium breve CCFM1310 can increase LDH activity.

[0035] Figure 7 The figure shows the activity of acid phosphatase (ACP) in the spleen, indicating that Bifidobacterium breve CCFM1310 can increase the activity of ACP.

[0036] Figure 8 The results show the α-diversity of gut microbiota, indicating that Bifidobacterium breve CCFM1310 can improve microbiota diversity.

[0037] Figure 9 The image shows mouse feces. Lachnospiraceae NK4A136 group The relative abundance indicates that Bifidobacterium breve CCFM1310 can increase the relative abundance of this genus.

[0038] ( Figures 1-9 In the text, "*", "**", "***", and "****" all indicate significant differences compared to the CTX group, with errors presented as Mean ± SEM. Detailed Implementation

[0039] The technical features of the present invention are further illustrated below through specific embodiments. The specific embodiments shown in the figures are currently the best, but these embodiments are not intended to limit the scope of protection of the present invention.

[0040] The mice used in the following examples were 6-week-old female SPF (Specific pathogen free) BALB / c mice, purchased from Vital Rivers; the reagents required for preparing the culture media used in the following examples were all purchased from Sinopharm Chemical Reagent Co., Ltd.; the cyclophosphamide (CTX) used for modeling in the following examples was purchased from Wuxi Lefus Co., Ltd.

[0041] The culture media involved in the following examples are as follows:

[0042] mMRS liquid culture medium: tryptone 10 g / L, beef extract 10 g / L, yeast extract 5 g / L, glucose 20 g / L, anhydrous sodium acetate 2 g / L, magnesium sulfate heptahydrate 0.5 g / L, manganese sulfate monohydrate 0.25 g / L, diammonium hydrogen citrate 2 g / L, dipotassium hydrogen phosphate trihydrate 2.6 g / L, Tween 80 mL / L, cysteine ​​hydrochloride 0.5 g / L.

[0043] mMRS solid culture medium: tryptone 10 g / L, beef extract 10 g / L, yeast extract 5 g / L, glucose 20 g / L, anhydrous sodium acetate 2 g / L, magnesium sulfate heptahydrate 0.5 g / L, manganese sulfate monohydrate 0.25 g / L, diammonium hydrogen citrate 2 g / L, dipotassium hydrogen phosphate trihydrate 2.6 g / L, Tween 80 mL / L, cysteine ​​hydrochloride 0.5 g / L, agar 20 g / L.

[0044] Example 1: Screening, Identification and Preservation of Strains

[0045] (1) Screening of strains

[0046] One g of fecal matter from healthy individuals in Hunan Province was serially diluted and spread onto mMRS solid medium (containing 10 μg / mL mupirocin antibiotic). The medium was incubated at 37℃ in an anaerobic environment for 72 h, and colony morphology was observed and recorded. Moist, raised, whitish-yellowish colonies were picked and streaked onto mMRS solid medium, and purified under anaerobic conditions at 37℃. This process was repeated three times to obtain purified single colonies. Single colonies were then streaked onto mMRS solid medium and incubated anaerobicly at 37℃ for 36 h. Gram staining was performed on the obtained colonies (Gram staining method referenced from the textbook "Industrial Microbial Breeding" by Zhuge Jian). Strains that were Gram-negative, had raised, whitish-yellowish colonies, were catalase-negative, and were fructose-6-phosphate kinase-positive were retained. One strain was obtained in this screening.

[0047] (2) Identification

[0048] Extract the genome of the strain obtained in step (1), amplify and sequence the 16S rDNA of the strain, and perform nucleic acid sequence alignment in NCBI-Blast. The results show that the strain is Bifidobacterium breve (Bifidobacterium breve). Bifidobacterium breve ).

[0049] The primers used for 16S rDNA amplification are as follows:

[0050] 27F: 5'-AGAGTTTGATCCTGGCTCAG-3';

[0051] 1492R: 5'-TACGGCTACCTTGTTACGACTT-3';

[0052] The 16S rDNA amplification procedure is as follows:

[0053] 95℃ for 5 min; 35 cycles (95℃ for 30 s; 55℃ for 30 s; 72℃ for 2 min); 72℃ for 10 min.

[0054] (3) Save

[0055] Single colonies were picked and inoculated into mMRS liquid medium and cultured anaerobically at 37°C for 24 h to obtain bacterial suspension. The bacterial suspension was centrifuged at 3000 rpm for 10 min in a centrifuge tube to collect bacterial cells. Sterile PBS buffer solution was added to the bacterial cells and centrifuged at 3000 rpm for 10 min in a centrifuge tube for washing to obtain washed bacterial cells. This operation was repeated 3 times. Sterile 30% (v / v) glycerol was added to the obtained bacterial cells and stored in glycerol tubes at -80°C.

[0056] After identification, the bacterium was deposited at the China General Microbiological Culture Collection Center (CGMCC) on June 7, 2023, with accession number CGMCC No. 63536. Simultaneously, the bacterium is also deposited in the culture bank of the Food Biotechnology Center of Jiangnan University, with accession number CCFM1310.

[0057] Example 2: Preparation of Bifidobacterium breve CCFM1310 bacterial suspension

[0058] (1) Take a bacterial suspension of Bifidobacterium breve CCFM1310 from a glycerol tube and streak it on mMRS solid medium. Incubate at 37°C for 48 h under anaerobic conditions to obtain a single colony. Pick a single colony and inoculate it into mMRS liquid medium. Incubate at 37°C for 48 h under anaerobic conditions for activation culture. Repeat this operation 3 times to obtain the activated bacterial suspension.

[0059] (2) The activated bacterial solution obtained in the above steps was inoculated into mMRS liquid medium at an inoculation rate of 2% (v / v). After incubation at 37°C for 24 h, the fermentation broth was obtained. The fermentation broth was centrifuged to collect the bacterial cells, which were then resuspended in physiological saline and the viable cell count was adjusted to 5 × 10⁻⁶. 9 CFU / mL was used to prepare a bacterial suspension.

[0060] Example 3: Effects of Bifidobacterium breve CCFM1310 on immune organs in an immunosuppressed mouse model

[0061] (1) The experimental animals were female SPF-grade BALB / c mice (6 weeks old, weighing 19-20 g) from Zhejiang Vital River Laboratory Animal Technology Co., Ltd., China. The mice were housed in polypropylene cages, with 8 mice per group. The cages were equipped with food and water, and the temperature (22℃) and relative humidity (50±10%) were controlled. The mice had free access to water.

[0062] (2) Establishment of an immunosuppressed mouse model

[0063] BALB / c mice were divided into a control group, a model group, and a CCFM1310 group, with 8 mice per group. After the adaptation period, each mouse in the model group and CCFM1310 group was injected intraperitoneally with cyclophosphamide (80 mg / kg bw), while the control group was injected with the same dose of physiological saline for three consecutive days.

[0064] (3) Experimental grouping and drug administration

[0065] Three days after the modeling process, the control group and the modeling group began daily gavage administration of sterile saline (0.2 mL / animal), while the CCFM1310 group was administered a daily gavage of bacterial suspension (1×10⁻⁶). 9 0.2 mL / animal (CFU / mL) was administered by gavage for 10 consecutive days.

[0066] (4) Measurement of immune organ index (IOI)

[0067] On day 14 of the experiment, after death due to cervical dislocation, an immediate dissection was performed. The thymus and spleen were removed, and other adhering tissues were carefully removed. The surface mucus was gently absorbed with absorbent paper before weighing. The experimental results are expressed as mean ± SEM.

[0068] IOI= ;

[0069] The results are as follows Figure 1 As shown, the thymus index of the model group treated with CTX decreased by 28.59% compared with the control group, while the spleen index was 31.9% higher than that of the control group due to splenomegaly. Compared with the model group, the thymus index of the CCFM1310 group mice was 32.91% higher than that of the model group, while the spleen index was 11.99% lower than that of the model group (p<0.05).

[0070] Example 4: Effect of Bifidobacterium breve CCFM1310 on white blood cell count in immunosuppressed mouse model

[0071] Blood was collected from the eyeballs and placed in 1.5 mL centrifuge tubes containing anticoagulant. The number of white blood cells in the mouse whole blood was then determined using a hematology analyzer. White blood cells are important immune cells in the human body and can be classified into granulocytes, monocytes, and lymphocytes based on their morphology. Results are as follows... Figure 2As shown, CTX can reduce the number of white blood cells in the blood of mice. The white blood cell count in the model group was 40.69% lower than that in the control group (p<0.01), while the white blood cell count in the CCFM1310 group was 56.34% higher than that in the model group (p<0.05). Lymphocyte counts showed that the CCFM1310 group had a higher count than the model group by 89.52% (p<0.01), and the neutrophil count in the CCFM1310 group increased by 57.83% compared to the model group, indicating that this bacterium can enhance the immune capacity of CTX-induced model mice.

[0072] Example 5: Effects of Bifidobacterium breve CCFM1310 on spleen tissue of immunosuppressed mouse model

[0073] After euthanizing the mice, a portion of the spleen tissue was harvested. The blood was rinsed away with physiological saline, fixed in 4% paraformaldehyde for 24 h, embedded in paraffin, and then sectioned into 5 μm sections. The sections were dewaxed with xylene and then stained with hematoxylin and eosin (H&E) for observation. Results are as follows: Figure 3 As shown, the spleen tissue in the blank control group had clear structures in each layer, with no significant changes in the number and size of white pulp, and a clear boundary between red and white pulp with no obvious abnormalities. In contrast, the model group had fewer white pulp cells; the red pulp was evenly distributed with a slightly unclear boundary between it and the white pulp; a large number of granulocytes and a small number of extramedullary hematopoietic cells were visible in the red pulp. After treatment with CCFM1310, the damage to the spleen tissue was improved.

[0074] Example 6: Effects of Bifidobacterium breve CCFM1310 on small intestinal tissue of immunosuppressed mice

[0075] After euthanizing the mice, a portion of small intestinal tissue was harvested. The blood was rinsed away with physiological saline, fixed in 4% paraformaldehyde for 24 h, embedded in paraffin, and then sectioned into 5 μm sections. The sections were dewaxed with xylene and then stained with hematoxylin and eosin (H&E) for observation. Results are as follows: Figure 4 As shown, the small intestine in the control group had a normal morphology and structure, with goblet cells distributed among the epithelial cells. The epithelium at the base of the intestinal villi invaginated to form Lee's crypts, and the muscularis mucosae composed of a double layer of smooth muscle cells separated the intestinal crypts from the submucosa. In contrast, the small intestine tissue in the model group showed loose and irregular arrangement of intestinal glands, a small amount of villi loss, unclear structure, exposed lamina propria, and separation of the villi mucosal epithelium from the lamina propria; a small amount of lymphocyte infiltration was also observed in the mucosal layer. In the bacterial irrigation group, all symptoms improved.

[0076] Example 7: Effect of Bifidobacterium breve CCFM1310 on immunoglobulin levels in immunosuppressed mouse model mice

[0077] Blood was collected from mouse eyeballs and aliquoted into clean, dry EP tubes. After standing at room temperature for 2 hours, the tubes were centrifuged at 2000 rpm / min for 10 minutes at 4°C. The serum was then stored at -80°C for later use. The levels of immunoglobulins (IgA, IgG, IgM) in the serum were determined using an ELISA kit, following the kit's instructions. The experimental results are as follows: Figure 5 As shown, the CTX modeling treatment significantly reduced the level of immunoglobulins in the serum. Compared with the control group, the levels of IgA, IgG, and IgM in the modeling group decreased by 34.81%, 42.62%, and 18.28%, respectively. However, after gavage administration of the strain of the present invention, the levels of IgA, IgG, and IgM in the serum increased by 115.3%, 75.17%, and 58%, respectively (p<0.05), exceeding the levels of the control group, indicating that the strain of the present invention has the function of enhancing humoral immunity.

[0078] Example 8: Effect of Bifidobacterium breve CCFM1310 on LDH activity in the spleen of immunosuppressed mice

[0079] Spleen tissue frozen at -80℃ was removed, and tissue lysis buffer was added at a ratio of 1:9. The tissue was homogenized using a high-throughput homogenizer, then centrifuged at 12000 g at 4℃ for 15 min. The supernatant was collected, and the LDH enzyme activity of the spleen was measured according to the instructions of a kit purchased from Nanjing Jiancheng. LDH is an enzyme involved in glycolysis, which is beneficial for promoting the immune function of macrophages. The results are as follows: Figure 6 The results showed that after CTX treatment, the LDH activity in the model group was 27.06% lower than that in the blank group, while after CCFM1310 treatment, the LDH enzyme activity was 55.26% higher than that in the model group (p<0.05).

[0080] Example 9: Effect of Bifidobacterium breve CCFM1310 on ACP activity in the spleen of immunosuppressed mice

[0081] Spleen tissue frozen at -80℃ was removed, and tissue lysis buffer was added at a ratio of 1:9. The tissue was homogenized using a high-throughput homogenizer, then centrifuged at 12000 g at 4℃ for 15 min. The supernatant was collected, and the spleen ACP enzyme activity was measured according to the instructions of a kit purchased from Nanjing Jiancheng. ACP, as a marker enzyme of macrophage lysosomal enzymes, can activate macrophages. The results are as follows: Figure 7 The results showed that after CTX treatment, the ACP activity in the model group was 24.76% lower than that in the blank group, while after CCFM1310 treatment, the ACP enzyme activity was 32.96% higher than that in the model group (p<0.05).

[0082] Example 10: Effects of Bifidobacterium breve CCFM1310 on the gut microbiota of immunosuppressed mice

[0083] Bacterial genomes were extracted from mouse feces using a fecal DNA extraction kit. Specific PCR amplification of the V3-V4 regions of the extracted genomic DNA was performed (upstream primer 341F: CCTAYGGGRBGCASCAG; downstream primer 806R: GGACTACNNGGGTATCTAAT). 16S rDNA sequencing was then performed to analyze changes in gut microbiota diversity. The results are shown below. Figure 8 As shown, compared with the control group, the Chao 1 index of the intestine in the model group was lower than that in the control group, while the Chao 1 index of the CCFM1310 group was not significantly different from that in the model group. Furthermore, compared with the control group, the Shannon and Simpson indices in the model group decreased by 4.38% and 1.59%, respectively, while compared with the model group, the Shannon and Simpson indices in the CCFM1310 group increased by 5.87% and 2.33%, respectively (p<0.05).

[0084] In addition, Welch's t-test was used to identify bacterial genera with significant changes in relative abundance, and the results are as follows: Figure 9 As shown, compared with the blank group, the modeling group Lachnospiraceae NK4A136 group The relative abundance of this genus was significantly reduced (p<0.05), while the relative abundance of this genus in the CCFM1310 group was 37.14% higher than that in the model group, showing a significant difference (p<0.05).

[0085] Example 11 Preparation of lyophilized formulation of Bifidobacterium breve CCFM1310

[0086] The specific steps are as follows:

[0087] (1) Activation of the strain: The bacterial solution of Bifidobacterium breve CCFM1310 was taken from the glycerol tube and streaked on the mMRS solid medium. It was cultured at 37℃ for 48 h under anaerobic conditions to obtain a single colony. The single colony was picked and inoculated into the mMRS liquid medium. It was cultured at 37℃ for 24 h under anaerobic conditions for activation. This operation was repeated 3 times to obtain the activated bacterial solution.

[0088] (2) The bacterial culture obtained in step (1) was inoculated into mMRS liquid medium at an inoculum rate of 2%, and anaerobic cultured at 37℃ for 24 h to obtain fermentation broth. The obtained fermentation broth was centrifuged at 8000 rpm for 20 min and the bacterial sludge was collected. The bacterial sludge was washed 3 times with physiological saline and then used for later use. The viable cell count was adjusted to 1×10⁻⁶. 11 CFU / mL.

[0089] (3) Preparation of freeze-drying protectant: Mix 100 g / L skim milk powder, 100 g / L trehalose, 160 g / L sucrose and the remaining water to obtain freeze-drying protectant.

[0090] (4) Add the above-prepared freeze-drying protectant to the fungal sludge obtained in step (2), wherein the weight of the freeze-drying protectant is 3 times the weight of the fungal sludge. After mixing evenly, perform vacuum freeze-drying and finally vacuum package the freeze-dried preparation.

[0091] Comparative Example 1

[0092] The specific implementation method is the same as in Example 3, except that Bifidobacterium breve CCFM1310 is replaced with Lactobacillus rhamnosus LV108 (disclosed in patent applications with publication numbers CN101407835A and CN110317891A). The results showed that the spleen index and thymus index of mice in the Lactobacillus rhamnosus group were 4.7±0.1 and 1.1±0.1, respectively, while those in the model group were 4.33±0.1 and 0.86±0.09, respectively, which were 7.87% and 27.9% higher than those in the model group.

[0093] Comparative Example 2

[0094] The specific implementation method is the same as in Examples 3-4, except that Bifidobacterium breve CCFM1310 is replaced with Bacillus coagulans 13002 (disclosed in the patent application document with publication number CN110734873A). The results showed that the percentage of lymphocytes in the mice in the Bacillus coagulans group was 72.68%±3.48%, while that in the model group was 59.30%±6.65%, which was higher than that in the model group (15.68%).

[0095] Comparative Example 3

[0096] The specific implementation method is the same as in Examples 3 and 7, except that Bifidobacterium breve CCFM1310 is replaced with Bifidobacterium lactis M8 (disclosed in the patent application document with publication number CN110157650A). The results showed that the IgA and IgG levels of mice in the Bifidobacterium lactis group were 126±16 µg / mL and 7.05±0.76 µg / mL, respectively, while the levels in the model group were 42±5 µg / mL and 4.92±0.91 µg / mL, respectively, which increased by 200% and 43.29% compared with the model group.

[0097] Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various modifications and alterations without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be determined by the claims.

Claims

1. A strain of Bifidobacterium breve ( Bifidobacterium breve strain CCFM1310, characterized in that, This strain was deposited at the Guangdong Provincial Center for Microbial Culture Collection on June 7, 2023, with accession number GDMCC No: 63536.

2. A microbial preparation containing the Bifidobacterium breve CCFM1310 as described in claim 1.

3. The use of the Bifidobacterium breve CCFM1310 as described in claim 1 in the preparation of immunomodulatory drugs.

4. The application according to claim 3, characterized in that, The applications include regulating the body's non-specific immune function, specific immune function, and intestinal immune function.

5. The application according to claim 3, characterized in that, The drug has at least one of the following functions: (1) Improves pathological damage to the spleen and small intestine tissues in individuals; (2) Increase the individual's immunoglobulin level; (3) Increase the number of white blood cells in an individual; (4) Increase the activity of individual acid phosphatase and lactate dehydrogenase; (5) Increase the abundance of gut microbiota in individuals.

6. A drug containing the Bifidobacterium breve CCFM1310 as described in claim 1.

7. The drug according to claim 6, characterized in that, The drug contains the aforementioned Bifidobacterium breve CCFM1310, as well as a drug carrier and / or pharmaceutical excipients.

8. The drug according to claim 6 or 7, characterized in that, The viable count of Bifidobacterium breve CCFM1310 in the drug is not less than 1×10⁻⁶. 10 CFU / g.

9. The use of the Bifidobacterium breve CCFM1310 as described in claim 1 in the preparation of health products that help enhance immunity.

Images